The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Risk for Myopathy With Statin Therapy in High-Risk Patients
Abstract
Emerging data suggest that the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) offer important benefits for the large population of individuals at high risk for coronary heart disease. This population encompasses a sizable portion of individuals who are also at high risk for drug-drug interactions due to their need for multiple medications. In general, statins are associated with a very small risk for myopathy (which may progress to fatal or nonfatal rhabdomyolysis); however, the potential for drug-drug interactions is known to increase this risk in specific high-risk groups. The incidence of myopathy associated with statin therapy is dose related and is increased when statins are used in combination with agents that share common metabolic pathways. Of particular concern is the potential for interactions with other lipid-lowering agents such as fibrates and niacin (nicotinic acid), which may be used in patients with mixed lipidemia, and with immunosuppressive agents, such as cyclosporine, which are commonly used in patients after transplantation. Clinicians should be alert to the potential for drug-drug interactions to minimize the risk of myopathy during long-term statin therapy in patients at high risk for coronary heart disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Self-citationPREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Effect of pravastatin on outcomes after cardiac transplantation
Kobashigawa, J. A., Katznelson, S., Laks, H., Johnson, J. A., Yeatman, L., Wang, X. M., Chia, D., Terasaki, P. I., Sabad, A., Cogert, G. A., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509073331003 · Cited by 1,301
Wood, D., De Backer, G., Faergeman, O., Graham, I., Mancia, G., & Pyörälä, K. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)90209-x · Cited by 1,255
Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials
LaRosa, J. C., He, J., & Vupputuri, S. (1999) · JAMA · doi:10.1001/jama.282.24.2340 · Cited by 1,246
Current Perspectives on Statins
Maron, D. J., Fazio, S., & Linton, M. F. (2000) · Circulation · doi:10.1161/01.cir.101.2.207 · Cited by 1,213
Second Joint Task Force of European (1998) · European Heart Journal · doi:10.1053/euhj.1998.1243 · Cited by 1,131
New insights into the pharmacodynamic and pharmacokinetic properties of statins
Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., & Bernini, F. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00045-5 · Cited by 796
Self-citationSerruys, P. W. J. C. (2002) · JAMA · doi:10.1001/jama.287.24.3215 · Cited by 719
Hayden, M., Pignone, M., Phillips, C., & Mulrow, C. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-2-200201150-00016 · Cited by 627
Cerivastatin and Reports of Fatal Rhabdomyolysis
Staffa, J. A., Chang, J., & Green, L. (2002) · New England Journal of Medicine · doi:10.1056/nejm200202143460721 · Cited by 626
Lennernäs, H., & Fager, G. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732050-00005 · Cited by 527
Wenke, K., Meiser, B., Thiery, J., Nagel, D., von Scheidt, W., Steinbeck, G., Seidel, D., & Reichart, B. (1997) · Circulation · doi:10.1161/01.cir.96.5.1398 · Cited by 444
Myopathy and Rhabdomyolysis Associated With Lovastatin-Gemfibrozil Combination Therapy
Pierce, L. R. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450010075034 · Cited by 428
Withdrawal of Cerivastatin from the World Market
Furberg, C. D., & Pitt, B. (2001) · Trials · doi:10.1186/cvm-2-5-205 · Cited by 400
Causes of death after renal transplantation
Briggs, J. D. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.8.1545 · Cited by 340
Efficacy and long-term adverse effect pattern of lovastatin
Tobert, J. A. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)90004-5 · Cited by 335
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320
Rhabdomyolysis in Patients Receiving Lovastatin after Cardiac Transplantation
(1988) · New England Journal of Medicine · doi:10.1056/nejm198801073180111 · Cited by 292
Pedersen, T. R. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.156.18.2085 · Cited by 286
HMG-CoA Reductase Inhibitors and Myotoxicity
Ucar, M., Mjorndal, T., & Dahlqvist, R. (2000) · Drug Safety · doi:10.2165/00002018-200022060-00003 · Cited by 279
Corpier, C. L. (1988) · JAMA · doi:10.1001/jama.260.2.239 · Cited by 237
Kashyap, M. L., McGovern, M. E., Berra, K., Guyton, J. R., Kwiterovich, P. O., Harper, W. L., Toth, P. D., Favrot, L. K., Kerzner, B., Nash, S. D., et al. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02338-4 · Cited by 235
Christians, U., Jacobsen, W., & Floren, L. C. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00016-3 · Cited by 220
Lipid-Lowering Drugs and Risk of Myopathy: A Population-Based Follow-Up Study
Gaist, D., Alberto García Rodríguez, L., Huerta, C., Hallas, J., & Sindrup, S. H. (2001) · Epidemiology · doi:10.1097/00001648-200109000-00017 · Cited by 210
The Contribution of P‐glycoprotein to Pharmacokinetic Drug‐Drug Interactions
Yu, D. K. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922012006 · Cited by 199
Kyrklund, C., Backman, J. T., Kivistö, K. T., Neuvonen, M., Laitila, J., & Neuvonen, P. J. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115542 · Cited by 191
Comparative Tolerability of the HMG-CoA Reductase Inhibitors
Farmer, J. A., & Torre-Amione, G. (2000) · Drug Safety · doi:10.2165/00002018-200023030-00003 · Cited by 181
Boyd, R. A., Stern, R. H., Stewart, B. H., Wu, X., Reyner, E. L., Zegarac, E. A., Randinitis, E. J., & Whitfield, L. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/009127000004000112 · Cited by 179
(1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00010-1 · Cited by 179
HMG-CoA Reductase Inhibitors (Statins) Characterized as Direct Inhibitors of P-Glycoprotein
Wang, E.-J., Casciano, C. N., Clement, R. P., & Johnson, W. W. (2001) · Pharmaceutical Research · doi:10.1023/a:1011036428972 · Cited by 176
The interaction of diltiazem with lovastatin and pravastatin*
Azie, N. E., Brater, D. C., Becker, P. A., Jones, D. R., & Hall, S. D. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90067-4 · Cited by 174
Clinical Pharmacokinetics of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors
Desager, J.-P., & Horsmans, Y. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199631050-00003 · Cited by 167
Olbricht, C., Wanner, C., Eisenhauer, T., Kliem, V., Doll, R., Boddaert, M., O'Grady, P., Krekler, M., Mangold, B., & Christians, U. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90034-5 · Cited by 165
Clinical Pharmacokinetics of Fluvastatin
Scripture, C. D., & Pieper, J. A. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140040-00003 · Cited by 163
MUCK, W., MAI, I., FRITSCHE, L., OCHMANN, K., ROHDE, G., UNGER, S., JOHNE, A., BAUER, S., BUDDE, K., & ROOTS, I. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70104-9 · Cited by 158
Arntz, H.-R., Agrawal, R., Wunderlich, W., Schnitzer, L., Stern, R., Fischer, F., & Schultheiß, H. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01230-3 · Cited by 158
Lovastatin, Nicotinic Acid, and Rhabdomyolysis
Reaven, P. D., & Witztum, J. L. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-7-597_2 · Cited by 152
Fischer, V., Johanson, L., Heitz, F., Tullman, R. H., Graham, E., Baldeck, J. P., & Robinson, W. T. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14919-7 · Cited by 149
Smith, P. F., Eydelloth, R. S., Grossman, S. J., Stubbs, R. J., Schwartz, M. S., Germershausen, J. I., Vyas, K. P., Kari, P. H., & MacDonald, J. S. (1991) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24759-0 · Cited by 146
Árnadóttir, M., Eriksson, L.-O., Thysell, H., & Karkas, J. D. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000187521 · Cited by 137
Mulder, A. B., van Lijf, H. J., Bon, M. A. M., Bergh, F. A. J. T. M. V. D., Touw, D. J., Neef, C., & Vermes, I. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(01)25429-0 · Cited by 135
The interaction of diltiazem with simvastatin
Mousa, O., Brater, D. C., Sundblad, K. J., & Hall, S. D. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.104609 · Cited by 131
Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin
Gruer, P. J. K., Vega, J. M., Mercuri, M. F., Dobrinska, M. R., & Tobert, J. A. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00442-7 · Cited by 130
Ichimaru, N., Takahara, S., Kokado, Y., Wang, J. D., Hatori, M., Kameoka, H., Inoue, T., & Okuyama, A. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(01)00438-5 · Cited by 130
Ballantyne, C. M., Radovančević, B., Farmer, J. A., Frazier, O. H., Chandler, L., Payton‐Ross, C., Cocanougher, B., Jones, P. H., Young, J. B., & Gotto, A. M. (1992) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(92)90340-s · Cited by 126
Self-citationInteractions with hydroxymethylglutaryl-coenzyme A reductase inhibitors
Garnett, W. R. (1995) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/52.15.1639 · Cited by 125
Bottorff, M. B., & Hansten, P. D. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.15.2273 · Cited by 124
Effect of fluconazole on plasma fluvastatin and pravastatin concentrations
Kantola, T., Backman, J. T., Niemi, M., Kivistö, K. T., & Neuvonen, P. J. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000127 · Cited by 122
Rhabdomyolysis due to interaction of simvastatin with mibefradil
Schmassmann-Suhijar, D., Bullingham, R. E. S., Gasser, R., Schmutz, J., & Haefeli, W. E. (1998) · The Lancet · doi:10.1016/s0140-6736(05)78613-x · Cited by 118
Rhabdomyolysis After Taking Atorvastatin With Gemfibrozil
Duell, P. B., Connor, W. E., & Illingworth, D. R. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00907-7 · Cited by 118
Regazzi, M. B., Iacona, I., Campana, C., Raddato, V., Lesi, C., Perani, G., Gavazzi, A., & Viganò, M. (1993) · PubMed · Cited by 114
Effect of fluvastatin on acute renal allograft rejection: A randomized multicenter trial
Holdaas, H., Jardine, A. G., Wheeler, D. C., Brekke, I. B., Conlon, P. J., Fellström, B., Hammad, A., Holme, I., Isoniemi, H., Moore, R. H., et al. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00010.x · Cited by 110
Self-citationAyanian, J. Z., Fuchs, C. S., & Stone, R. M. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-8-682 · Cited by 109
Dujovne, C. A., Chremos, A. N., Pool, J. L., Schnaper, H. W., Bradford, R. H., Shear, C. L., Higgins, J., Downton, M., Franklin, F. A., Nash, D. T., et al. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90053-z · Cited by 109
Bradford, R. H., Shear, C. L., Chremos, A. N., Dujovne, C. A., Franklin, F. A., Grillo, R. B., Higgins, J., Langendörfer, A., Nash, D. T., Pool, J. L., et al. (1994) · The American Journal of Cardiology · doi:10.1016/0002-9149(94)90307-7 · Cited by 109
Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy
POGSON, G. W., Kindred, L. H., & Carper, B. G. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00034-x · Cited by 105
Rhabdomyolysis Associated with Concomitant Use of Atorvastatin and Cyclosporine
Maltz, H. C., Balog, D. L., & Cheigh, J. S. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.19039 · Cited by 104
Pharmacokinetics of the combination of fluvastatin and gemfibrozil
Spence, J. D., Muñoz, C. E., Hendricks, L., Latchinian, L., & Khouri, H. E. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(05)80024-4 · Cited by 102
Treatment of hyperlipidemia with combined niacin–statin regimens
Guyton, J. R., & Capuzzi, D. M. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00955-2 · Cited by 98
Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation
KEOGH, A. M., Macdonald, P. S., Kaan, A., Aboyoun, C. L., Spratt, P. M., & Mundy, J. A. (2000) · The Journal of Heart and Lung Transplantation · doi:10.1016/s1053-2498(00)00077-2 · Cited by 96
Posvar, E. L., Radulovic, L. L., Cilla, D. D., Whitfield, L. R., & Sedman, A. J. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04242.x · Cited by 91
Fluvastatin with and without niacin for hypercholesterolemia
Jacobson, T. A., Chin, M. M., Fromell, G. J., Jokubaitis, L. A., & Amorosa, L. F. (1994) · The American Journal of Cardiology · doi:10.1016/0002-9149(94)90088-4 · Cited by 88
Self-citationBezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety
Gavish, D., Leibovitz, E., Shapira, I., & Rubinstein, A. (2000) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2000.00646.x · Cited by 87
Pharmacokinetics of Fluvastatin and Specific Drug Interactions
Smith, H. T., Jokubaitis, L. A., Troendle, A. J., Hwang, D.-Y., & Robinson, W. T. (1993) · American Journal of Hypertension · doi:10.1093/ajh/6.11.375s · Cited by 86
Goldberg, R., & Roth, D. (1996) · Transplantation · doi:10.1097/00007890-199612150-00005 · Cited by 85
Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes
Yeo, K. R., & Yeo, W. W. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2001.01386.x · Cited by 83
Rhabdomyolysis associated with lovastatin and erythromycin use.
Spach, D. H., Bauwens, J. E., Clark, C. D., & Burke, W. G. (1991) · PubMed Central · Cited by 81
Rhabdomyolysis Associated With Simvastatin–Gemfibrozil Therapy
Tal, A., RAJESHAWARI, M., & Isley, W. L. (1997) · Southern Medical Journal · doi:10.1097/00007611-199705000-00018 · Cited by 72
Holdaas, H., Fellström, B., Holme, I., Nyberg, G., Fauchald, P., Jardine, A. G., Grönhagen‐Riska, C., Madsen, S., Neumayer, H. ‐., Cole, E., et al. (2001) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182670100800202 · Cited by 71
Self-citationRhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil
Alexandridis, G., Παππάς, Γ., & Elisaf, M. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00514-3 · Cited by 67
Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil
van Puijenbroek, E., du Buf-Vereijken, P. W. G., Spooren, P. F. M. J., et al. (1996) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1996.48879000.x · Cited by 67
Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis.
Kanathur, N., Mathai, M. G., Byrd, R. P., Fields, C. L., & Roy, T. M. (2001) · PubMed · Cited by 63
Pauciullo, P., Borgnino, C., Paoletti, R., Mariani, M., & Mancini, M. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(00)00379-8 · Cited by 63
Rhabdomyolysis and Simvastatin
Deslypère, J. P., & Vermeulen, A. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-4-342_1 · Cited by 58
Joshi, H., Fakes, M. G., & Serajuddin, A. T. M. (1999) · Pharmacy and Pharmacology Communications · doi:10.1211/146080899128734820 · Cited by 58
Ozdemir, O., Boran, M., Gökçe, V., Uzun, Y., Koçak, B., & Korkmaz, S. (2000) · PubMed · Cited by 56
Jardine, A. G., & Holdaas, H. (1999) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.1999.00252.x · Cited by 54
Self-citationPlotkin, E., Bernheim, J., Benchetrit, S., Mor, A., & Korzets, Z. (2000) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/15.5.740 · Cited by 53
Insull, W., Isaacsohn, J. L., Kwiterovich, P. O., Ma, P., Brazg, R., Dujovne, C. A., Shan, M., Shugrue-Crowley, E., Ripa, S., Tota, R. R., et al. (2000) · Journal of International Medical Research · doi:10.1177/147323000002800201 · Cited by 52
Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil
Bermingham, R. P., Whitsitt, T. B., Smart, M. L., Nowak, D., & Scalley, R. D. (2000) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/57.5.461 · Cited by 52
Potential Interaction between Warfarin and Fluvastatin
Trilli, L. E., Kelley, C. L., Aspinall, S. L., & Kroner, B. A. (1996) · Annals of Pharmacotherapy · doi:10.1177/106002809603001207 · Cited by 51
Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism?
Nordin, C., Dahl, M., Eriksson, M., & Sjöberg, S. (1997) · The Lancet · doi:10.1016/s0140-6736(05)66238-1 · Cited by 50
Pancreatitis and Rhabdomyolysis Associated with Lovastatin-Gemfibrozil Therapy
Abdul-Ghaffar, N. U. A. M. A., & El-Sonbaty, M. R. (1995) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199512000-00027 · Cited by 47
Rhabdomyolysis with Simvastatin Use
Berland, Y., Coponat, V., Durand, C., Baz, M., Laugier, R., & Musso, J. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000186289 · Cited by 47
Argov, Z. (2000) · Current Opinion in Neurology · doi:10.1097/00019052-200010000-00006 · Cited by 45
Kusus, M., Stapleton, D. D., Lertora, J. J. L., Simon, E. E., & Dreisbach, A. W. (2000) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200012000-00007 · Cited by 44
Lovastatin-induced acute rhabdomyolysis
Kogan, A., & Orenstein, S. (1990) · Postgraduate Medical Journal · doi:10.1136/pgmj.66.774.294 · Cited by 44
Rhabdomyolysis Associated with Concurrent Use of Simvastatin and Diltiazem
Peces, R., & Pobes, A. (2001) · The Nephron journals/Nephron journals · doi:10.1159/000046056 · Cited by 41
Sabia, H. D., Prasad, P., Smith, H. T., et al. (2001) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200105000-00002 · Cited by 41
Csako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40
Cerivastatin-Induced Rhabdomyolysis
Rodríguez, M. L., Fernández, C. M., & Navarro‐González, J. F. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-7-200004040-00031 · Cited by 39
Mastroianni, C. M., d’Ettorre, G., Forcina, G., Lichtner, M., Corpolongo, A., Coletta, S., & Vullo, V. (2001) · AIDS · doi:10.1097/00002030-200104130-00029 · Cited by 39
Biotransformation of Pravastatin Sodium(I)
Kitazawa, E., Tamura, N., Iwabuchi, H., Uchiyama, M., Muramatsu, S., Takahagi, H., & Tanaka, M. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.1457 · Cited by 37
Frequency of creatine kinase elevation during treatment with fluvastatin
Benghozi, R., Bortolini, M., Jia, Y., Isaacsohn, J. L., Troendle, A. J., & Gonasun, L. M. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02209-3 · Cited by 36
Rhabdomyolysis due to simvastatin in a transplant patient: are some statins safer than others?
Stirling, C., & Isles, C. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.4.873 · Cited by 36
Massive Rhabdomyolysis and Simvastatin
Bizzaro, N., Bagolin, E., Milani, L., Cereser, C., & Finco, B. (1992) · Clinical Chemistry · doi:10.1093/clinchem/38.8.1504 · Cited by 36
Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine
Rodríguez, J. A., Crespo-Leiro, M. G., Paniagua, M. J., Cuenca, J. J., Hermida, L. F., Juffé, A., & Castro-Beiras, A. (1999) · Transplantation Proceedings · doi:10.1016/s0041-1345(99)00445-5 · Cited by 32
Rhabdomyolysis and Acute Renal Failure after Changing Statin-Fibrate Combinations
Oldemeyer, J. B., Lund, R. J., Koch, M., Meares, A. J., & Dunlay, R. (2000) · Cardiology · doi:10.1159/000047304 · Cited by 31
SoRelle, R. (2001) · PubMed · Cited by 31
Dose Dependency of Fluvastatin Pharmacokinetics in Serum Determined by Reversed Phase HPLC
Siekmeier, R., Lattke, P., Mix, C., Park, J.-W., & Jaross, W. (2001) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840100600205 · Cited by 30
Acute Rhabdomyolysis Associated With Cerivastatin Therapy
García-Valdecasas-Campelo, E., Gonzalez-Reimers, E., Lopez-Lirola, A., Rodriguez-Rodriguez, E., & Santolaria-Fernandez, F. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.6.893 · Cited by 30
Pharmacotherapy of hypercholesterolaemia: statins in clinical practice
Moghadasian, M. H., Mancini, G. J., & Frohlich, J. J. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.4.683 · Cited by 28
Ballantyne, C. M., Bourge, R. C., Domalik, L. J., Eisen, H. J., Fishbein, D. P., Kubo, S. H., Lake, K. D., Radovančević, B., Taylor, D. O., Ventura, H. O., et al. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00358-x · Cited by 20
Self-citationLau, T. K., Leachman, D. R., & Lufschanowski, R. (2001) · Europe PMC (PubMed Central) · Cited by 18
Tomlinson, B., & Lan, I. W. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00691-x · Cited by 17
Southworth, M. R., & Mauro, V. F. (1997) · Annals of Pharmacotherapy · doi:10.1177/106002809703100417 · Cited by 17
Davidson, M. H. (2001) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840100600302 · Cited by 15
Self-citationYang, B., Hounslow, N. J., Sedman, A. J., & Forgue, S. T. (1996) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1996.tb04212.x · Cited by 14
Salivary Homocyst(E)Ine Concentrations
Boulot-Tolle, M., Chadefaux, B., & Kamoun, P. (1992) · Clinical Chemistry · doi:10.1093/clinchem/38.8.1504a · Cited by 13
Knöll, R., Ciafone, R. A., & Galen, M. A. (1993) · PubMed · Cited by 11
Combination of Pravastatin and Cyclosporin in Transplant Patients
&NA; (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732020-00006 · Cited by 7
Cited by
Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-5686-z · Cited by 1,226
Prepared by: British Cardiac Society, B. H. S. (2005) · Heart · doi:10.1136/hrt.2005.079988 · Cited by 1,216
Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update
Schachter, M. (2005) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00299.x · Cited by 1,211
(2007) · PubMed · Cited by 953
Holdaas, H., Fellström, B., Jardine, A. G., Holme, I., Nyberg, G., Fauchald, P., Grönhagen-Riska, C., Madsen, S., Neumayer, H.-H., Cole, E., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13638-0 · Cited by 919
Self-citation
Metadata
- Authors
- Ballantyne, C. M., Corsini, A., Davidson, M. H., Holdaas, H., Jacobson, T. A., Leitersdorf, E., März, W., Reckless, J. P. D., & Stein, E. A.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2003-03-10
- Volume
- 163
- Issue
- 5
- Pages
- 553
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2029471511
- Cited by
- 453
- References
- 121
- FWCI
- 48.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.